Cost Effectiveness of Fulvestrant 500 Mg in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer in the UK

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.214
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Comparison of Fulvestrant Plus a Targeted Agent With Fulvestrant Alone in Hormone Receptor-Positive Advanced Breast Cancer That Progressed on Prior Endocrine Therapy: A Meta-Analysis

OncoTargets and Therapy
OncologyPharmacology
2018English

Overall Survival and Progression-Free Survival With Endocrine Therapy for Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer: Review

Therapeutic Advances in Medical Oncology
Oncology
2017English

Predictors of Prolonged Benefit From Palbociclib Plus Fulvestrant in Women With Endocrine-Resistant Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in PALOMA-3

European Journal of Cancer
Cancer ResearchOncology
2018English

Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2012English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

Fulvestrant Treatment Is Associated With Cholesterol Plasma Level Reduction in Hormone Receptor-Positive Metastatic Breast Cancer Patients

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2009English

Efficacy and Safety of Palbociclib Plus Endocrine Therapy in North American Women With Hormone Receptor‐positive/Human Epidermal Growth Factor Receptor 2‐negative Metastatic Breast Cancer

Breast Journal
Internal MedicineSurgeryOncology
2020English

Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy